MEDINCELL Aktie

 

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

A year marked by solid execution, with Continued UZEDY® ramp-up, supporting royalty growth Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva1 The first AbbVie program progressing toward the initiation of clinical development The expansion of both partnered and internal R&D pipelines Continued strengthening of the technology platform MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Key Financial Highlights Total revenues   €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the revenue model   Operating result   €(20.8) million, reflecting a planned increase in operating expenses to €45.0 million (+17% year-over-year) to support pipeline expansion and long-term value creation   Liquidity position   €84.8 million2 strengthened by successful fund raising of €48.2 million in March 2026, attracting top-tier US and European healthcare investors Medincell continues to transition...

A year marked by solid execution, with Continued UZEDY® ramp-up, supporting royalty growth Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva1 The first AbbVie program progressing toward the initiation of clinical development The expansion of both partnered and internal R&D pipelines Continued strengthening of the technology platform MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights   Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the revenue model Operating result €(20.8) million, reflecting a planned increase in operating expenses to €45.0 million (+17% year-over-year) to support pipeline expansion and long-term value creation Liquidity position €84.8 million2 strengthened by successful fund raising of €48.2 million in March 2026, attracting top-tier US and European healthcare investors Medincell continues to transition towards multiple commerciali...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. Videoconference in English, 6:00pm CEST / 12:00pm ET >https://www.medincell.com/annual-results-2025-2026-register/ During the videoconference, Medincell's management team will provide an overview of the company's performance and strategic outlook, followed by a Q&A session in English. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments ac...

PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the Market......

TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a 62% increase from $39 million in Q1 2025 and a 15% increase from $55 million in Q4 2025. Medincell receives mid‑ to high‑single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to the achievement of annual sales thresholds. UZEDY is a 1-Month and 2-Month subcutaneous risperidone LAI (Long-Acting Injectable). It received U.S. FDA approval for schizophrenia in April 2023 and for Bipolar I Disorder in October 2025. Olanzapine LAI The New Drug Application (NDA) for once‑monthly olanzapine LAI for the treatment of schizophrenia in adults was accepted by the U.S. FDA in February 2026, with a regulatory decision anticipated in Q4 2026. In Europe, acceptance of the Marketing Authorization Application (MAA) is expected in ...

Success of the transaction with €48 million raised. Participation of leading international Healthcare specialist investors. Funds raised are expected to support long‑term value creation, primarily by expanding partnering opportunities, maximizing the value captured from future collaborations, and strengthening Medincell's proprietary long‑acting injectable (LAI) technology platform through targeted innovation.MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced the successful pricing of its Private Placement (as defined below) for a total amount of €48 million through an offering to international institutional investors. Both US an...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) ......

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia....

Medincell's overall ESG rating has been upgraded from C+ to B by ISS, a leading global provider of sustainability ratings Medincell is ranked in the first decile of the Pharmaceuticals & Biotechnology sector Medincell's ESG disclosure is classified at a very high transparency levelMONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announces that ISS has upgraded the company's ESG rating from C+ to B. Medincell is ranked within the first decile of the Pharmaceuticals & Biotechnology sector, benefits from ISS ESG Prime Status, and achieves a very high level of ESG disclosure transparency. This updated rating is based on ISS ESG's independent assessment of multiple extra‑financial criteria, including: Social factors and product responsibility, Governance and business ethics requirements as defined within the ISS ESG methodology, and Selected env...

OLANZAPINE LAI: EU Submission Expected in Q2 2026MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results: About UZEDY® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva's initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds. About OLANZAPINE LAI Olanzapine Long-Acting Injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation for a broad population of patients living with schizophrenia.1 Submission of Olanzapine LAI in the European Union for the treatment of schizophrenia in adults is expected in Q2 2026 Following submission to...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Event Date Annual results 2025-2026 (April 2025-March 2026) Tuesday, June 16, 2026 General Meeting Thursday, September 10, 2026 Half-Year results 2026-2027 (April-September 2026) Tuesday, December 8, 2026 About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit. Risperidone LAI was the first treatment based on BEPO® technology to receive F...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

(April 1st, 2025 - September 30, 2025) MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): “We are pleased with the company's growth and momentum. We have entered the most transformative years in Medincell's history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell's growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading the way, while further expanding and diversifying our pipeline and collaborations with leading pharmaceutical partners.” Stéphane Postic, CFO of Medincell: “Revenues are growing and are expected to accelerate in the coming years with Olanzapine LAI. We have refined our investment plan to allocate resources strategically, with discipline and ambition. This approach is designed to create sustainable value and position Medincell for long-term success.” Consolidated fi...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025) > Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/ > Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/ Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several ...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell, a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy Officer, U.S. Finance. Over the past two years, Grace has played a key and successful role within the Medincell team, with the initial and decisive shaping of the company's US capital growth strategy and advancing cross-border initiatives. As Medincell enters a pivotal growth phase, Dr. Kim will build on this foundation to lead and execute the next stages of company's U.S. capital growth strategy, driving long-term value for patients, partners, and investors. About Dr Grace Kim Dr Grace Kim serves as Medincell's Chief Strategy Officer, U.S. Finance, acting as an execution partner for the company's U.S. capital strategy and global expansion. Dr Grace Kim has two decades' experience in Capital Markets, Corporate Strategy, and Investment Banking. Grace previously served as Chief Strategy Officer of Molecula...

PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Ad......